Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension (LIFE) study

被引：7
作者：
Devereux, RB
Lyle, PA
机构：
[1] Cornell Univ, Weill Med Coll, Div Cardiol, New York, NY 10021 USA
[2] Merck Res Labs, West Point, PA 19486 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2004年 / 5卷 / 11期
关键词：
albuminuria; angiotensin II; angiotensin-receptor antagonist; antihypertensive agents; diabetes mellitus; hypertension; isolated systolic hypertension; left ventricular hypertrophy; Losartan; stroke; uric acid;
D O I：
10.1517/14656566.5.11.2311
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class. It has been approved for the treatment of hypertension, and may be used alone or in combination with other anti hypertensive agents. Based on the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, losartan has been approved for the reduction of cardiovascular events in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. Based on the Reduction of Endpoints in NOW with the Angiotensin II Antagonist Losartan (RENAAL) study, losartan is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria, in patients with Type 2 diabetes. The focus of this review is the LIFE study.
引用
收藏
页码：2311 / 2320
页数：10
相关论文
共 50 条
[41]   Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension [J].
Picca, M ;
Agozzino, F ;
Pelosi, G .
ADVANCES IN THERAPY, 2004, 21 (02) :76-86
[42]   Left atrial size and risk of major cardiovascular events during antihypertensive treatment -: Losartan intervention for endpoint reduction in hypertension trial [J].
Gerdts, Eva ;
Wachtell, Kristian ;
Omvik, Per ;
Otterstad, Jan Erik ;
Oikarinen, Lasse ;
Boman, Kurt ;
Dahlof, Bjorn ;
Devereux, Richard B. .
HYPERTENSION, 2007, 49 (02) :311-316
[43]   Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension [J].
Maurizio Picca ;
Francesco Agozzino ;
Giancarlo Pelosi .
Advances in Therapy, 2004, 21 :76-86
[44]   Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy [J].
Olsen, MH ;
Wachtell, K ;
Tuxen, C ;
Fossum, E ;
Bang, LE ;
Hall, C ;
Ibsen, H ;
Rokkedal, J ;
Devereux, RB ;
Hildebrandt, PR .
JOURNAL OF HYPERTENSION, 2005, 23 (05) :1083-1090
[45]   Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study [J].
Bang, Casper N. ;
Okin, Peter M. ;
Kober, Lars ;
Wachtell, Kristian ;
Gottlieb, Alice Bendix ;
Devereux, Richard B. .
JOURNAL OF HYPERTENSION, 2014, 32 (03) :667-672
[46]   A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy [J].
Aslam H. Anis ;
Huiying Sun ;
Sonia Singh ;
John Woolcott ;
Bohdan Nosyk ;
Marc Brisson .
PharmacoEconomics, 2006, 24 :387-400
[47]   Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients -: Losartan intervention for endpoint reduction in hypertension study [J].
Ibsen, H ;
Olsen, MH ;
Wachtell, K ;
Borch-Johnsen, K ;
Lindholm, LH ;
Mogensen, CE ;
Dahlöf, B ;
Devereux, RB ;
de Faire, U ;
Fyhrquist, F ;
Julius, S ;
Kjeldsen, SE ;
Lederballe-Pedersen, O ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wan, Y .
HYPERTENSION, 2005, 45 (02) :198-202
[48]   Change in systolic left ventricular performance after 3 years of antihypertensive treatment -: The Losartan intervention for Endpoint (LIFE) study [J].
Wachtell, K ;
Palmieri, V ;
Olsen, MH ;
Gerdts, E ;
Papademetriou, V ;
Nieminen, MS ;
Smith, G ;
Dahlöf, B ;
Aurigemma, GP ;
Devereux, RB .
CIRCULATION, 2002, 106 (02) :227-232
[49]   Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients -: Losartan intervention for end point reduction in hypertension study [J].
Narayan, P ;
Papademetriou, V ;
Wachtell, K ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
de Simone, G ;
Dahlöf, B ;
Fyhrquist, F ;
Hoieggen, A ;
Devereux, RB .
HYPERTENSION, 2006, 47 (05) :868-873
[50]   Albuminuria predicts cardiovascular outcome with losartan versus atenolol in patients with diabetes, hypertension and left ventricular hypertrophy. A life diabetes substudy [J].
Ibsen, H ;
Olsen, MH ;
Wachtell, K ;
Borch-Johnsen, K ;
Lindholm, L ;
Dahloef, B ;
Snapinn, S .
AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) :2A-2A
12345